Class / Patent application number | Description | Number of patent applications / Date published |
514348000 | Chalcogens bonded directly to at least two ring carbons of the six-membered hetero ring | 34 |
20080200520 | Iron Modulators - Iron modulator compounds of formula (I) are provided for treating amyloidoses wherein R | 08-21-2008 |
20080242706 | Fluorinated derivatives of deferiprone - The present invention relates to novel derivatives of deferiprone. In particular, the present invention relates to fluorinated derivatives of deferiprone or pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising same, processes for the manufacture thereof and their use in the treatment of neurodegenerative diseases caused by the presence of free iron or iron accumulation in neural tissues and in diseases wherein excess iron must be removed or redistributed. | 10-02-2008 |
20080293779 | Methods of treating humans undergoing injection of a contrast agent - A human undergoing an injection of a contrast agent is treated by the administration of an iron chelator. Administration of the iron chelator can essentially prevent the onset of acute renal failure in a human. Administration of the iron chelator can reduce the severity of the acute renal failure and/or reduce the severity of kidney disease consequent to the acute renal failure. | 11-27-2008 |
20090023784 | USE OF DEFERIPRONE AND METHODS TO TREAT AND/OR PREVENT FRIEDREICH ATAXIA RESULTING FROM INTRACELLULAR MISHANDLING OF IRON - A therapeutically effective amount of deferiprone or deferasirox or physiologically acceptable salts thereof for the prevention, stabilization, treatment, or reversal of iron-induced FRDA disease in patients resulting from mitochondrial iron-induced damage to preferentially reduce the iron stores in the mitochondria. Also for the treatment of other conditions affecting the brain where a key element in the generation of the resultant pathology is the intracellular mishandling of iron. | 01-22-2009 |
20090099239 | Antiviral Compounds and Methods - The present invention relates to novel compounds and compositions having antiviral activity. The invention also relates to methods for the therapeutic or prophylactic treatment of viral infections in mammals. | 04-16-2009 |
20090137640 | POTENTIATOR FOR RADIATION THERAPY COMPRISING PYRIDINE DERIVATIVE AS ACTIVE INGREDIENT - The present invention relates to a radiotherapy enhancer that can reduce the radiation dose and adverse drug reactions when used in combination with a cancer radiotherapy. There is provided a radiotherapy enhancer comprising, as an active ingredient, a pyridine derivative represented by general formula (1): | 05-28-2009 |
20090156647 | Method for maintaining physiological pH levels during intensive physical exercise - A nutritional supplement comprising at least a therapeutically effective amount of pyridoxine α-hydroxyisocaproate is provided by the present invention. The ingredients of the present nutritional supplement act substantially simultaneously to maintain physiological blood and muscular pH and increase the time to muscular fatigue in a mammal during periods of repetitive forceful muscular exercise. A method of use is provided by the present disclosure. | 06-18-2009 |
20090156648 | Preparations containing pyridoxine and alpha-hydroxyisocaproic acid (HICA) - The present invention relates to stable salts of pyridoxine and α-hydroxyisocaproic acid (HICA) endowed with enhanced nutritional and/or therapeutical efficacy in respect to their individual effects and to solid compositions containing such salts, particularly suited to oral administration. A method of preparation is also provided. | 06-18-2009 |
20100041714 | BI-ARYL AMINOTETRALINES - The invention is concerned with the compounds of formula I: | 02-18-2010 |
20100099720 | Gene Polymorphisms as Sex-Specific Predictors in Cancer Therapy - The invention provides compositions and methods for determining the likelihood of gender-specific successful treatment with 5-FU/oxaliplatin or an equivalent of each thereof. The methods comprise determining the genomic polymorphism present in a predetermined region of a gene of interest and correlating the polymorphism to the predictive response. Patients identified as responsive are then treated with the appropriate therapy. | 04-22-2010 |
20100137376 | AMIDE COMPOUND AND METHOD FOR CONTROLLING PLANT DISEASE USING THE SAME - Disclosed is a plant disease control agent containing an amide compound represented by formula (1) below which has an excellent plant disease controlling effect as an active ingredient. | 06-03-2010 |
20100173951 | NOVEL METHODS - The invention relates to the novel chemical compounds of the formula (I): (I) in free or salt form, its use in the treatment of NET and/or SERT mediated conditions, e.g., depression, vasomotor symptoms, e.g., hot flashes and other diseases or conditions mediated by NET and/or SERT. | 07-08-2010 |
20100173952 | METALLOPROTEIN INHIBITORS - The present invention relates to metalloprotein inhibitors comprising:
| 07-08-2010 |
20110039897 | LIQUID FORMULATION FOR DEFERIPRONE WITH PALATABLE TASTE - An oral pharmaceutical liquid formulation comprising deferiprone and a taste masking composition, said taste masking composition comprising an effective amount of a sweetener (such as sucralose) per litre of liquid composition, an effective amount of a thickening and suspension aid, (for example hydroxyethylcellulose), per litre of liquid composition, an effective amount of a humectant (such as glycerin) per litre of liquid composition, and an effective amount of at least one flavoring agent, wherein a final form of said taste-masked pharmaceutical has a substantially non-bitter and palatable taste. | 02-17-2011 |
20110065758 | Compositions and assays for treatment and diagnosis of helicobacter pylori infection and conditions - Methods of diagnosing | 03-17-2011 |
20110092550 | COMBINATIONS OF IMAZALIL AND HYDROXYPYRIDONES - The present invention relates to combinations of imazalil, or a salt thereof, and hydroxypyridones which provide an improved biocidal effect. More particularly, the present invention relates to compositions comprising a combination of imazalil, or a salt thereof, together with one or more hydroxypyridones selected from 1-hydroxy-2-pyridinone, ciclopirox, ciclopirox olamine, piroctone, piroctone olamine and rilopirox in respective proportions to provide a synergistic biocidal effect. Compositions comprising these combinations are useful for the protection of any living or non-living material, such as crops, plants, fruits, seeds, objects made of wood, thatch or the like, engineering material, biodegradable material and textiles against deterioration due to the action of microorganisms such as bacteria, fungi, yeasts, algae, viruses, and the like. | 04-21-2011 |
20110144167 | Prolyl Hydroxylase Inhibitors - The invention described herein relates to certain pyrimidinedione N-substituted glycine derivatives of formula (I) | 06-16-2011 |
20110184029 | PYRIDONE DERIVATIVES AS NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS - The present invention relates to 2-pyridone derivatives of Formula I or IV | 07-28-2011 |
20110213001 | PHARMACEUTICAL COMPOSITIONS - The object of the present invention is to provide a pharmaceutical composition that inhibits expression of iNOS and COX-2 without inhibiting NF-κB. The pharmaceutical composition that inhibits expression of iNOS and COX-2 without inhibiting NF-κB contains DTCM glutarimide of the Formula (I) as an effective ingredient, thereby being able to inhibit nitric oxide (NO) production and prostaglandin production. | 09-01-2011 |
20120041032 | METALLOPROTEIN INHIBITORS - The present invention relates to metalloprotein inhibitors comprising: a. an organic substituent and at least one zinc binding group (ZBG) covalently attached thereto; or b. a ZBG substituted by a side chain wherein the ZBG is of formula (I): wherein X is O or S and each R | 02-16-2012 |
20120077852 | HYDROXYPYRIDINONES FOR THE LOCAL TREATMENT OF SKIN MICROCIRCULATORY DISORDERS - The application of hydroxypyridonone in effective amounts as external agent for patients suffering from skin micro-circulatory disorders (SMD) provides for a significant amelioration of subject conditions. Accordingly, the new use of hydroxypyridonones as external anti-inflammatory agent thereby combined with the depletion of hemosiderin residues offers a suitable treatment to SMD sufferers. | 03-29-2012 |
20120095061 | Fluorinated Derivatives of Deferiprone - The present invention relates to novel derivatives of deferiprone. In particular, the present invention relates to fluorinated derivatives of deferiprone or pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising same, processes for the manufacture thereof and their use in the treatment of neurodegenerative diseases caused by the presence of free iron or iron accumulation in neural tissues and in diseases wherein excess iron must be removed or redistributed. | 04-19-2012 |
20120264790 | ACYLAMINO-SUBSTITUTED CYCLIC CARBOXYLIC ACID DERIVATIVES AND THEIR USE AS PHARMACEUTICALS - The present invention relates to compounds of the formula I, | 10-18-2012 |
20130012549 | Method for the Treatment, Alleviation of Symptoms of, Relieving, Improving and Preventing a Cognitive Disease, Disorder or Condition - The present invention provides uses of a salt adduct comprising at least one positively charged moiety being a pyridoxine or a derivative thereof and at least one carboxylated 5- to 7-membered lactam ring, optionally additionally substituted, for the preparation of a medicament for the treatment, alleviation of symptoms of, relieving, improving and preventing a cognitive disease, disorder or condition in a subject. Additionally, the invention provides use of said salt adducts for the preparation of medicaments for the improvement of cognitive functions in a healthy subject. | 01-10-2013 |
20130023569 | Use of Deferiprone for Treatment and Prevention of Iron-Related Eye Disorders - There is provided use of orally available or topically applied deferiprone for prevention of iron-induced eye damage. The use may be for preparation of a medicament or in a method of preventing iron-induced eye damage to an eye of a subject at risk for iron-induced eye damage, the method comprising administering a prophylactically effective amount of deferiprone to the subject. There is also provided the use of deferiprone for treatment of iron-related eye disorders. The use may be for preparation of a medicament or in a method of treatment of damage to an eye of a having eye damage associated with iron, the method comprising topically administering a therapeutically effective amount of deferiprone to the subject. | 01-24-2013 |
20130190365 | Use of Deferiprone and Methods to Treat and/or Prevent Friedreich Ataxia Resulting from Intracellular Mishandling of Iron - A therapeutically effective amount of deferiprone or deferasirox or physiologically acceptable salts thereof for the prevention, stabilization, treatment, or reversal of iron-induced FRDA disease in patients resulting from mitochondrial iron-induced damage to preferentially reduce the iron stores in the mitochondria. Also for the treatment of other conditions affecting the brain where a key element in the generation of the resultant pathology is the intracellular mishandling of iron. | 07-25-2013 |
20130197038 | Compositions And Methods For Neovascularization - The invention is directed to a method of inducing angiogenesis at a site in an individual in need thereof comprising administering locally to the site an effective amount of one or more agents that induce hypoxia induced factor 1α (HIF-1α). In another aspect, the invention is directed to a method of inducing angiogenesis at a site in an individual in need thereof comprising administering locally to the site an effective amount of one or more agents that induce hypoxia induced factor 1α (HIF-1α) and one or more lysophospholipids. In addition, the invention is directed to methods of generating prevascularized tissue, methods of generating a vascular network in a device and compositions thereof. | 08-01-2013 |
20130203822 | COMPOUNDS FOR TREATMENT OF TUMORS BEARING DEREGULATED MYC ONCOPROTEINS - Compound of Formula (I): wherein R | 08-08-2013 |
20130267564 | BENZYLOXYPYRIMIDINE DERIVATIVE, AGRICULTURAL/ HORTICULTURAL INSECTICIDE COMPRISING DERIVATIVE AND METHOD FOR USING SAME - A benzyloxypyrimidine derivative represented by the formula (I) | 10-10-2013 |
20140031395 | Positive Allosteric Modulators of the Alpha 7 Nicotinic Acetylcholine Receptor and uses Thereof - The present invention relates to compounds useful in the positive modulation of the alpha 7 nicotinic acetylcholine receptor (α7nAChR). The invention also relates to the use of these compounds in the treatment or prevention of a broad range of diseases in which the positive modulation of α7nAChR is advantageous, including neurodegenerative and neuropsychiatric diseases and also inflammatory diseases. | 01-30-2014 |
20140088158 | ACYLAMINO-SUBSTITUTED CYCLIC CARBOXYLIC ACID DERIVATIVES AND THEIR USE AS PHARMACEUTICALS - The present invention relates to compounds of the formula I, | 03-27-2014 |
20160083346 | Fluorinated Derivatives of 3-Hydroxypyridin-4-Ones - Compounds of Formula I which are derivatives of 3-Hydroxypyridin-4-ones. The compounds may be used in treatment of a medical condition related to a toxic concentration of iron. The compounds may be used for preparation of a medicament for treatment of a medical condition related to a toxic concentration of iron. The medical condition related to a toxic concentration of iron may be selected from the group consisting of: cancer, pulmonary disease, progressive kidney disease and Friedreich's ataxia. | 03-24-2016 |
20160199361 | Method of Inducing An Anti-Retroviral Immune Response By Counter-Acting Retro-Virus Induced Anti-Apoptosis | 07-14-2016 |
20160376235 | Pyridone FabI Inhibitors and Uses Thereof - The present invention provides novel 2-pyridone compounds and 4-pyridone compounds and methods of treating a subject infected with a pathogen of | 12-29-2016 |